Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups

Chronic lymphocytic leukaemia (CLL) consists of two biologically and clinically distinct subtypes defined by the abundance of somatic hypermutation (SHM) affecting the Ig variable heavy-chain locus (IgHV). The molecular mechanisms underlying these subtypes are incompletely understood. Here, we present a comprehensive whole-genome sequencing analysis of somatically acquired genetic events from 46 CLL patients, including a systematic comparison of coding and non-coding single-nucleotide variants, copy number variants and structural variants, regions of kataegis and mutation signatures between IgHVmut and IgHVunmut subtypes. We demonstrate that one-quarter of non-coding mutations in regions of kataegis outside the Ig loci are located in genes relevant to CLL. We show that non-coding mutations in ATM may negatively impact on ATM expression and find non-coding and regulatory region mutations in TCL1A, and in IgHVunmut CLL in IKZF3, SAMHD1,PAX5 and BIRC3. Finally, we show that IgHVunmut CLL is dominated by coding mutations in driver genes and an aging signature, whereas IgHVmut CLL has a high incidence of promoter and enhancer mutations caused by aberrant activation-induced cytidine deaminase activity. Taken together, our data support the hypothesis that differences in clinical outcome and biological characteristics between the two subgroups might reflect differences in mutation distribution, incidence and distinct underlying mutagenic mechanisms.

[1]  Axel Benner,et al.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. , 2008, Blood.

[2]  Thomas Zichner,et al.  DELLY: structural variant discovery by integrated paired-end and split-read analysis , 2012, Bioinform..

[3]  H. Döhner,et al.  Treatment resistance in chronic lymphocytic leukemia–the role of the p53 pathway , 2009, Leukemia & lymphoma.

[4]  T. Stankovic,et al.  Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia , 1999, The Lancet.

[5]  L. Pasqualucci,et al.  Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. , 2011, Blood.

[6]  Rob Pieters,et al.  Prognostic Value of Rare IKZF1 deletions in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: An International Collaborative Study , 2014 .

[7]  W. Tapper,et al.  Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease , 2016, Leukemia.

[8]  Francesco Bertoni,et al.  Genome‐wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion , 2008, British journal of haematology.

[9]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[10]  A. Valencia,et al.  Non-coding recurrent mutations in chronic lymphocytic leukaemia , 2015, Nature.

[11]  Paul T. Groth,et al.  The ENCODE (ENCyclopedia Of DNA Elements) Project , 2004, Science.

[12]  H. Döhner,et al.  Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. , 1999, Blood.

[13]  M. Stratton,et al.  Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.

[14]  E. Campo,et al.  The genomic landscape of chronic lymphocytic leukemia: clinical implications , 2013, BMC Medicine.

[15]  K. Ickstadt,et al.  TCL1A and ATM are co-expressed in chronic lymphocytic leukemia cells without deletion of 11q , 2013, Haematologica.

[16]  Steven J. M. Jones,et al.  Recurrent targets of aberrant somatic hypermutation in lymphoma , 2012, Oncotarget.

[17]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[18]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[19]  Bing Li,et al.  Histone H3 Methylation by Set2 Directs Deacetylation of Coding Regions by Rpd3S to Suppress Spurious Intragenic Transcription , 2005, Cell.

[20]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[21]  David Botstein,et al.  Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.

[22]  S. Swerdlow WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[23]  Martin A. Nowak,et al.  Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.

[24]  M. Minden,et al.  Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling , 2012, Nature.

[25]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[26]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[27]  J. Michael Cherry,et al.  Principles of metadata organization at the ENCODE data coordination center , 2016, Database J. Biol. Databases Curation.

[28]  Semyon Kruglyak,et al.  Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms , 2013, Bioinform..

[29]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[30]  A. Regev,et al.  Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia , 2012, Clinical Cancer Research.

[31]  Luca Laurenti,et al.  Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. , 2012, Blood.

[32]  S. Gabriel,et al.  Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution , 2015, Nature Communications.

[33]  Xiao-Jie Yan,et al.  IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. , 2012, Blood.

[34]  A. Pettitt,et al.  TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations , 2010, Leukemia.

[35]  J. Byrd,et al.  DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia , 2016, Nature Genetics.

[36]  D. Catovsky,et al.  TCL1 is activated by chromosomal rearrangement or by hypomethylation , 2001, Genes, chromosomes & cancer.

[37]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[38]  D Rizopoulos,et al.  Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study , 2016, Leukemia.

[39]  L. Pasqualucci,et al.  Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. , 2014, Blood.

[40]  D. Catovsky,et al.  Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial , 2016, Leukemia.

[41]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[42]  A. Rebollo,et al.  Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications. , 2011, Blood.

[43]  H. Döhner,et al.  Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. , 2005, Blood.

[44]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[45]  K. Do,et al.  Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). , 2014, Blood.

[46]  L. Larocca,et al.  Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome , 2012, British journal of haematology.

[47]  O. Bernard,et al.  Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages. , 2010, Leukemia research.

[48]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[49]  L. Pasqualucci,et al.  Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. , 2011, Blood.

[50]  Jenny Taylor,et al.  Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. , 2012, Blood.

[51]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[52]  Y. Pekarsky,et al.  Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. , 2006, Cancer research.

[53]  Gordon Cook,et al.  APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma , 2014, Nature Communications.

[54]  S. Robson,et al.  Nucleosome-Interacting Proteins Regulated by DNA and Histone Methylation , 2010, Cell.

[55]  L. Pasqualucci,et al.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.

[56]  P. Timpson Faculty Opinions recommendation of The topography of mutational processes in breast cancer genomes. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[57]  Xiaobo Song,et al.  Reversal Effect of ST6GAL 1 on Multidrug Resistance in Human Leukemia by Regulating the PI3K/Akt Pathway and the Expression of P-gp and MRP1 , 2014, PloS one.

[58]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[59]  Michalis K. Titsias,et al.  SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. , 2014, Blood.

[60]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[61]  H. Döhner,et al.  Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. , 2016, Blood.

[62]  Y. Tu,et al.  Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.

[63]  L. Lopez,et al.  Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia , 2017, Leukemia.

[64]  H. Döhner,et al.  Risk stratification in chronic lymphocytic leukemia. , 2006, Seminars in oncology.

[65]  N. Chiorazzi,et al.  B cell receptor signaling in chronic lymphocytic leukemia. , 2013, Trends in immunology.

[66]  Manolis Kellis,et al.  ChromHMM: automating chromatin-state discovery and characterization , 2012, Nature Methods.

[67]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[68]  Gouri Nanjangud,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[69]  R. Dalla‐Favera,et al.  Mutations of NOTCH 1 are an independent predictor of survival in chronic lymphocytic leukemia , 2012 .